{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:12:12Z","timestamp":1791389532920,"version":"4.3.3"},"reference-count":49,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2022,5,31]]},"DOI":"10.5582\/irdr.2022.01039","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T18:10:05Z","timestamp":1653415805000},"page":"63-69","source":"Crossref","is-referenced-by-count":14,"title":["Expanded newborn bloodspot screening: developed country examples and what can be done in Turkey"],"prefix":"10.5582","volume":"11","author":[{"given":"\u00c7a\u011flar","family":"Fidan","sequence":"first","affiliation":[{"name":"Ba\u015fkent University Faculty of Medicine, Department of Public Health, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"\u00d6r\u00fcn","sequence":"additional","affiliation":[{"name":"Ba\u015fkent University Faculty of Medicine, Department of Public Health, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131 Beg\u00fcm","family":"Alper","sequence":"additional","affiliation":[{"name":"Ba\u015fkent University Faculty of Medicine, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7i\u011fdem Naz","family":"\u00dcnver","sequence":"additional","affiliation":[{"name":"Ba\u015fkent University Faculty of Medicine, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer Can","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Ba\u015fkent University Faculty of Medicine, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"U\u011furlu","sequence":"additional","affiliation":[{"name":"Ba\u015fkent University Faculty of Medicine, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recep","family":"Akdur","sequence":"additional","affiliation":[{"name":"Ba\u015fkent University Faculty of Medicine, Department of Public Health, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Taruscio","sequence":"additional","affiliation":[{"name":"National Centre for Rare Diseases, Istituto Superiore di Sanit\u00e0, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Castro R, de Chalendar M, Vajda I, van Breukelen, Courbier S, Hedley V, Montefusco M, Nielsen SJ, Dan D. Rare Diseases. In: Handbook Integrated Care. Second edition (Amelung V, Stein V, Suter E, Goodwin N, Nolte E, Balicer R, eds.). Springer International Publishing; 2021; pp. 763-782.","DOI":"10.1007\/978-3-030-69262-9_44"},{"key":"2","unstructured":"2. EURORDIS. Harmonised Newborn Screening in Europe - a window of opportunity that we should not miss! Published 2021. <i>https:\/\/www.eurordis.org\/news\/harmonised-newborn-screening-europe-window-opportunity-we-should-not-miss<\/i> (accessed November 7, 2021)."},{"key":"3","unstructured":"3. Satman \u0130, G\u00fcd\u00fck \u00d6, Yemenici M, Ert\u00fcrk N. Nadir Hastal\u0131klar Raporu. Published 2019. <i>https:\/\/www.tuseb.gov.tr\/tuhke\/uploads\/genel\/files\/haberler\/nadir_hastaliklar_raporu.pdf<\/i> (accessed November 7, 2021). (in Turkish)"},{"key":"4","unstructured":"4. EURORDIS. What is rare disease? <i>https:\/\/www.eurordis.org\/content\/what-rare-disease<\/i> (accessed November 8, 2021)."},{"key":"5","unstructured":"5. European Union. Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Published 1999.<i> https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32000R0141&amp;from=EN<\/i> (accessed November 10, 2021)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Groft SC, Posada de la Paz M. Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data. In: Rare Diseases Epidemiology: Update and Overview. Second edition (Posada de la Paz M, Taruscio D, Groft SC, eds.). Springer, 2017; pp. 3-21.","DOI":"10.1007\/978-3-319-67144-4_1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. The Lancet. Making rare diseases a public-health and research priority. Lancet. 2008; 371:1972.","DOI":"10.1016\/S0140-6736(08)60842-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ramalle-G\u00f3mara E, Dom\u00ednguez-Garrido E, G\u00f3mezEgu\u00edlaz M, Marzo-Sola ME, Ram\u00f3n-Trapero JL, Gil-de-G\u00f3mez J. Education and information needs for physicians about rare diseases in Spain. Orphanet J Rare Dis. 2020; 15:18.","DOI":"10.1186\/s13023-019-1285-0"},{"key":"9","unstructured":"9. Taruscio D, Kodra Y, Ferrari G, Vittozzi L, National Rare Diseases Registry Collaborating Group. The Italian national rare diseases registry. Blood Transfus. 2014; 12 Suppl 3:s606-13."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, Trefz FK, Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF. Efficacy and outcome of expanded newborn screening for metabolic diseases \u2012 Report of 10 years from South-West Germany. Orphanet J Rare Dis. 2011; 6:44.","DOI":"10.1186\/1750-1172-6-44"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med. 2016; 4:653-661.","DOI":"10.1016\/S2213-2600(16)00053-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, Hoffmann GF, Vittozzi L. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis. 2012; 35:603-611.","DOI":"10.1007\/s10545-012-9483-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Burgard P, Rupp K, Lindner M, Haege G, Rigter T, Weinreich SS, Loeber JG, Taruscio D, Vittozzi L, Cornel MC, Hoffmann GF. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis. 2012; 35:613-625.","DOI":"10.1007\/s10545-012-9484-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cornel MC, Rigter T, Weinreich SS, Burgard P, Hoffmann GF, Lindner M, Gerard Loeber J, Rupp K, Taruscio D, Vittozzi L. A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document. Eur J Hum Genet. 2014; 22:12-17.","DOI":"10.1038\/ejhg.2013.90"},{"key":"15","unstructured":"15. Wilson JMG, Jungner G. Principles and practice of screening for disease. 1968. <i>https:\/\/apps.who.int\/iris\/handle\/10665\/37650<\/i> (accessed November 7, 2021)"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Dobrow MJ, Hagens V, Chafe R, Sullivan T, Rabeneck L. Consolidated principles for screening based on a systematic review and consensus process. CMAJ. 2018; 190:E422-E429.","DOI":"10.1503\/cmaj.171154"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Andermann A, Blancquaert I, Beauchamp S, D\u00e9ry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008; 86:317-319.","DOI":"10.2471\/BLT.07.050112"},{"key":"18","unstructured":"18. RACGP. Newborn Screening. <i>https:\/\/www.racgp.org.au\/clinical-resources\/clinical-guidelines\/key-racgpguidelines\/view-all-racgp-guidelines\/genomics\/newborn-screening<\/i> (accessed November 9, 2021)."},{"key":"19","unstructured":"19. Newborn Screening Ontario. Diseases Screened. <i>https:\/\/www.newbornscreening.on.ca\/en\/about-screening\/diseases-screened<\/i> (accessed November 9, 2021)."},{"key":"20","unstructured":"20. Brockow I, Blankenstein O, Ceglarek U, <i>et al<\/i>. National Screening Report Germany 2018. 2021. <i>https:\/\/www.screening-dgns.de\/Pdf\/Screeningreports\/DGNS-Screeningreport-e_2018.pdf<\/i> (accessed November 12, 2021)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Konstantopoulou V, Zeyda M. 25th Annual Meeting of the German Society of Newborn Screening. Int J Neonatal Screen. 2018; 4:17.","DOI":"10.3390\/ijns4020017"},{"key":"22","unstructured":"22. SMA NBS Alliance. Status of Newborn Screening for Spinal Muscular Atrophy. Published 2021. <i>https:\/\/www.sma-screening-alliance.org\/map\/<\/i> (accessed November 9, 2021)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lund AM, Wibrand F, Skogstrand K, B\u00e6kvad-Hansen M, Gregersen N, Andresen BS, Hougaard DM, Dun\u00f8 M, Olsen RKJ. Use of Molecular Genetic Analyses in Danish Routine Newborn Screening. Int J Neonatal Screen. 2021; 7:50.","DOI":"10.3390\/ijns7030050"},{"key":"24","unstructured":"24. National Health Services. Newborn blood spot test. <i>https:\/\/www.nhs.uk\/conditions\/baby\/newborn-screening\/blood-spot-test\/<\/i> (accessed November 9, 2021)."},{"key":"25","unstructured":"25. Ministry of Health Israel. Diseases tested in neonatal screening tests. <i>https:\/\/www.health.gov.il\/Subjects\/Genetics\/newborn_neonatal_screening\/Pages\/disease_testing.aspx<\/i> (accessed November 9, 2021). (in Hebrew)"},{"key":"26","unstructured":"26. Taruscio D, Kodra Y, Amicosante AMV, Bacco G, Burlina A, la Marca G, Leonardi A, Privitera MG, Salvatore F, Segato A, Tamburini C, Vaccarotto M, Piccioli A. Expanded Neonatal Screening Programme in the Italian Regions and Autonomous Provinces. State of the Art up to June 30, 2019. Rapporti ISTISAN 20\/18. 2020.<i> https:\/\/www.iss.it\/documents\/20126\/0\/20-18+web.pdf\/5f473c42-88df-5e07-28c9-90d1d1cf9377?t=1603173542977<\/i> (accessed November 9, 2021). (in Italian)"},{"key":"27","unstructured":"27. National Institute for Public Health and the Environment. Newborn Blood Spot Screening Fact Sheet. 2020. <i>https:\/\/www.pns.nl\/sites\/default\/files\/2021-02\/Newborn bloodspot screening fact sheet dec2020_UK_0.pdf<\/i> (accessed November 9, 2021)."},{"key":"28","unstructured":"28. National Screening Unit. About the test. Published 2017. Accessed November 9, 2021. <i>https:\/\/www.nsu.govt.nz\/pregnancy-newborn-screening\/newborn-metabolic-screening-programme-heel-prick-test\/about-test<\/i> (accessed November 9, 2021)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Tangeraas T, S\u00e6ves I, Klingenberg C, <i>et al<\/i>. Performance of expanded newborn screening in Norway supported by post-analytical bioinformatics tools and rapid second-tier DNA analyses. Int J Neonatal Screen. 2020; 6:51.","DOI":"10.3390\/ijns6030051"},{"key":"30","unstructured":"30. T.C. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Halk Sa\u011fl\u0131\u011f\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc \u00c7ocuk ve Ergen Sa\u011fl\u0131\u011f\u0131 Dairesi Ba\u015fkanl\u0131\u011f\u0131. Yenido\u011fan Metabolik ve Endokrin Hastal\u0131k Tarama Program\u0131 (NTP). <i>https:\/\/hsgm.saglik.gov.tr\/tr\/cocukergen-tp-liste\/yenidogan_tarama_programi.html <\/i>(accessed November 1, 2021). (in Turkish)"},{"key":"31","unstructured":"31. Department of Health Wadsworth Center. Screened Disorders. <i>https:\/\/www.wadsworth.org\/programs\/newborn\/screening\/screened-disorders<\/i> (accessed November 9, 2021)."},{"key":"32","unstructured":"32. Hacettepe N\u00fcfus Et\u00fctleri Enstit\u00fcs\u00fc, T.C. Cumhurba\u015fkanl\u0131\u011f\u0131Strateji ve B\u00fct\u00e7e Ba\u015fkanl\u0131\u011f\u0131, T\u00dcB\u0130TAK. T\u00fcrkiye N\u00fcfus ve Sa\u011fl\u0131k Ara\u015ft\u0131rmas\u0131 2018. 2019. <i>http:\/\/fs.hacettepe.edu.tr\/hips\/dosyalar\/Ara%C5%9Ft%C4%B1rmalar%20-%20raporlar\/2018%20TNSA\/TNSA2018_ana_Rapor_compressed.pdf<\/i> (accessed November 9, 2021). (in Turkish)"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Tezel B, Dilli D, Bolat H, Sahman H, Ozba\u015f S, Ac\u0131can D, Ertek M, K\u00f6se MR, Dilmen U. The development and organization of newborn screening programs in Turkey. J Clin Lab Anal. 2014; 28:63-69.","DOI":"10.1002\/jcla.21645"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Loeber JG, Platis D, Zetterstr\u00f6m RH, <i>et al<\/i>. Neonatal screening in Europe revisited: An ISNS perspective on the current state and developments since 2010. Int J Neonatal Screen. 2021; 7:15.","DOI":"10.3390\/ijns7010015"},{"key":"35","unstructured":"35. T\u00fcrkiye B\u00fcy\u00fck Millet Meclisi Nadir Hastal\u0131klar Ara\u015ft\u0131rma Komisyonu. ALS, SMA, DMD, MS Hastal\u0131klar\u0131nda ve Kesin Tedavisi Bilinmeyen Di\u011fer Hastal\u0131klarda Uygulanan Tedavi ve Bak\u0131m Y\u00f6ntemleri Ile Bu Hastal\u0131klara Sahip Ki\u015filer ve Yak\u0131nlar\u0131n\u0131n Ya\u015fad\u0131klar\u0131 Sorunlar\u0131n ve \u00c7\u00f6z\u00fcmlerinin Belirlenmesi Amac\u0131yla Kurulan Meclis Ara\u015ft\u0131rma. 2020. <i>https:\/\/www5.tbmm.gov.tr\/sirasayi\/donem27\/yil01\/ss199.pdf <\/i>(accessed November 12, 2021). (in Turkish)"},{"key":"36","unstructured":"36. EURORDIS. EURORDIS position paper: key principles for newborn screening; 2021. <i>https:\/\/www.eurordis.org\/newbornscreening<\/i> (accessed November 11, 2021)."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Wilcken B. Expanded newborn screening: reducing harm, assessing benefit. J Inherit Metab Dis. 2010; 33(Suppl 2):S205-S210.","DOI":"10.1007\/s10545-010-9106-6"},{"key":"38","unstructured":"38. World Health Organization Regional Office for Europe. Screening Programmes: A Short Guide. Increase Effectiveness, Maximize Benefits and Minimize Harm. 2020. <i>https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/330829\/9789289054782-eng.pdf<\/i> (accessed November 9, 2021)."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Tiwana SK, Rascati KL, Park H. Cost-effectiveness of expanded newborn screening in Texas. Value Health. 2012; 15:613-621.","DOI":"10.1016\/j.jval.2012.02.007"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Posset R, Gropman AL, Nagamani SCS, <i>et al<\/i>. Impact of diagnosis and therapy on cognitive function in urea cycle disorders. Ann Neurol. 2019; 86:116-128.","DOI":"10.1002\/ana.25492"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Landau YE, Waisbren SE, Chan LMA, Levy HL. Long-term outcome of expanded newborn screening at Boston children&apos;s hospital: benefits and challenges in defining true disease. J Inherit Metab Dis. 2017; 40:209-218.","DOI":"10.1007\/s10545-016-0004-4"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Balascakov\u00e1 M, Holubov\u00e1 A, Skalick\u00e1 V, Zemkov\u00e1 D, Kracmar P, Gonsorc\u00edkova L, Camajov\u00e1 J, Pisk\u00e1ckov\u00e1 T, Lebl J, Drev\u00ednek P, Gregor V, V\u00e1vrov\u00e1 V, Votava F, Macek M Jr. Pilot newborn screening project for cystic fibrosis in the Czech Republic: Defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease. J Cyst Fibros. 2009; 8:224-227.","DOI":"10.1016\/j.jcf.2009.01.002"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Waters D, Adeloye D, Woolham D, Wastnedge E, Patel S, Rudan I. Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. J Glob Health. 2018; 8:021102.","DOI":"10.7189\/jogh.08.021102"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. van Rijt WJ, Koolhaas GD, Bekhof J, Heiner Fokkema MR, de Koning TJ, Visser G, Schielen PC, van Spronsen FJ, Derks TG. Inborn errors of metabolism that cause sudden infant death: A systematic review with implications for population neonatal screening programmes. Neonatology. 2016; 109:297-302.","DOI":"10.1159\/000443874"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. de Bitencourt FH, Schwartz IVD, Vianna FSL. Infant mortality in Brazil attributable to inborn errors of metabolism associated with sudden death: a time-series study (2002-2014). BMC Pediatr. 2019; 19:52.","DOI":"10.1186\/s12887-019-1421-y"},{"key":"46","unstructured":"46. World Health Organization. Sustainable Development Goals (SDGs). SDG 3 targets. <i>https:\/\/www.who.int\/health-topics\/sustainable-development-goals#tab=tab_2 <\/i>(accessed June 28, 2021)."},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Akdur R. Temel Kavramlar. In: Sa\u011fl\u0131k Bilimlerinde ARA\u015eTIRMA VE TEZ YAPMA REHBER\u0130 (Projelendirme, Uygulama, Rapor Yazma). \u0130kinci Bask\u0131 ; Ankara, Turkey, 2019: pp. 1-28.","DOI":"10.14527\/9786050370133.01"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Wilson RD, De Bie I, Armour CM, <i>et al<\/i>. Joint SOGC-CCMG opinion for reproductive genetic carrier screening: An update for all Canadian providers of maternity and reproductive healthcare in the era of direct-to-consumer testing. J Obstet Gynaecol Can. 2016; 38:742-762.e3.","DOI":"10.1016\/j.jogc.2016.06.008"},{"key":"49","unstructured":"49. The American College of Obstetricians and Gynecologists (ACOG). Carrier Screening for Genetic Condition. Published 2017. <i>https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2017\/03\/carrier-screening-for-genetic-conditions#s1<\/i> (accessed January 5, 2022)."}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/11\/2\/11_2022.01039\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T01:50:29Z","timestamp":1655517029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/11\/2\/11_2022.01039\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2022.01039","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"article-number":"2022.01039"}}